Translarne

Showing 1 posts of 1 posts found.

DMD

The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?

January 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs

The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …

Latest content